Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera

IF 4.5 2区 医学 Q1 ONCOLOGY Cancer Science Pub Date : 2024-09-16 DOI:10.1111/cas.16341
Sho Uemura, Yasuaki Kabe, Minoru Kitago, Sachiko Matsuda, Yuta Abe, Yasushi Hasegawa, Shutaro Hori, Masayuki Tanaka, Yutaka Nakano, Yasunori Sato, Makoto Itonaga, Masayuki Ono, Tatsuya Kawakami, Makoto Suematsu, Yuko Kitagawa
{"title":"Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera","authors":"Sho Uemura,&nbsp;Yasuaki Kabe,&nbsp;Minoru Kitago,&nbsp;Sachiko Matsuda,&nbsp;Yuta Abe,&nbsp;Yasushi Hasegawa,&nbsp;Shutaro Hori,&nbsp;Masayuki Tanaka,&nbsp;Yutaka Nakano,&nbsp;Yasunori Sato,&nbsp;Makoto Itonaga,&nbsp;Masayuki Ono,&nbsp;Tatsuya Kawakami,&nbsp;Makoto Suematsu,&nbsp;Yuko Kitagawa","doi":"10.1111/cas.16341","DOIUrl":null,"url":null,"abstract":"<p>Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy due to the difficulty in diagnosis and poor prognosis because of the high recurrence rate, necessitating reliable biomarkers to improve the diagnosis and prognosis. However, the existing markers have limitations. We previously identified extracellular vesicles (EVs) recognized by O-glycan-binding lectins (<i>Amaranthus caudatus</i> agglutinin [ACA]) as a novel diagnostic biomarker for PDAC using an EV-counting system (ExoCounter). This retrospective study analyzed changes in ACA-positive EVs in perioperative PDAC serum and its association with prognosis using ExoCounter. Absolute EV levels in the pre- and postoperative sera of 44 patients who underwent curative pancreatectomy for PDAC were quantified using ExoCounter. The carbohydrate antigen 19-9 levels declined in most samples postoperatively, and presented no correlation with poor prognosis. In contrast, ACA-positive EVs increased in serum at 7 days postoperatively in 27 of 44 patients (61.4%). We therefore divided participants with ACA-positive EVs before and after surgery into elevation and decline groups. The overall survival (OS) and recurrence-free survival (RFS) of patients with higher ACA-positive EVs were significantly shorter than those with lower ACA-positive EVs (26.1 months vs. not reached, <i>P</i> = 0.018; 11.9 vs. 38.6 months, <i>P</i> = 0.013). Multivariable analysis revealed that ACA-positive EV elevation in postoperative serum was an independent prognostic factor for poor OS (hazard ratio [HR] = 3.891, <i>P</i> = 0.023) and RFS (HR = 2.650, <i>P</i> = 0.024). The detection of ACA-positive EVs in perioperative serum may be used to predict the prognosis of PDAC in the early postoperative period.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16341","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16341","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy due to the difficulty in diagnosis and poor prognosis because of the high recurrence rate, necessitating reliable biomarkers to improve the diagnosis and prognosis. However, the existing markers have limitations. We previously identified extracellular vesicles (EVs) recognized by O-glycan-binding lectins (Amaranthus caudatus agglutinin [ACA]) as a novel diagnostic biomarker for PDAC using an EV-counting system (ExoCounter). This retrospective study analyzed changes in ACA-positive EVs in perioperative PDAC serum and its association with prognosis using ExoCounter. Absolute EV levels in the pre- and postoperative sera of 44 patients who underwent curative pancreatectomy for PDAC were quantified using ExoCounter. The carbohydrate antigen 19-9 levels declined in most samples postoperatively, and presented no correlation with poor prognosis. In contrast, ACA-positive EVs increased in serum at 7 days postoperatively in 27 of 44 patients (61.4%). We therefore divided participants with ACA-positive EVs before and after surgery into elevation and decline groups. The overall survival (OS) and recurrence-free survival (RFS) of patients with higher ACA-positive EVs were significantly shorter than those with lower ACA-positive EVs (26.1 months vs. not reached, P = 0.018; 11.9 vs. 38.6 months, P = 0.013). Multivariable analysis revealed that ACA-positive EV elevation in postoperative serum was an independent prognostic factor for poor OS (hazard ratio [HR] = 3.891, P = 0.023) and RFS (HR = 2.650, P = 0.024). The detection of ACA-positive EVs in perioperative serum may be used to predict the prognosis of PDAC in the early postoperative period.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过检测围手术期血清中 O-糖改变的细胞外囊泡预测 PDAC 的预后
胰腺导管腺癌(PDAC)是一种致命的恶性肿瘤,由于诊断困难和高复发率导致预后不良,因此需要可靠的生物标志物来改善诊断和预后。然而,现有的标志物存在局限性。此前,我们利用一种EV计数系统(ExoCounter)发现,O-糖结合凝集素(Amaranthus caudatus agglutinin [ACA])识别的细胞外囊泡(EV)是PDAC的一种新型诊断生物标志物。这项回顾性研究利用 ExoCounter 分析了 PDAC 围手术期血清中 ACA 阳性 EV 的变化及其与预后的关系。使用 ExoCounter 对 44 名接受胰腺癌根治性切除术的患者术前和术后血清中的 EV 绝对水平进行了量化。大多数样本的碳水化合物抗原 19-9 水平在术后均有所下降,且与预后不良无相关性。相比之下,44 例患者中有 27 例(61.4%)在术后 7 天血清中的 ACA 阳性 EV 增加。因此,我们将手术前后出现 ACA 阳性 EVs 的患者分为升高组和下降组。ACA阳性EV较高的患者的总生存期(OS)和无复发生存期(RFS)明显短于ACA阳性EV较低的患者(26.1个月对未达到,P = 0.018;11.9个月对38.6个月,P = 0.013)。多变量分析显示,术后血清中 ACA 阳性 EV 升高是不良 OS(危险比 [HR] = 3.891,P = 0.023)和 RFS(HR = 2.650,P = 0.024)的独立预后因素。围手术期血清中ACA阳性EV的检测可用于预测PDAC术后早期的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
期刊最新文献
Issue Information In this issue Issue Information In this issue Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1